Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Semaglutide (Wegovy) is FDA-approved for chronic weight management (with criteria) and has strong clinical trial evidence for meaningful average weight loss when paired with lifestyle support
Health Canada has approved RYBELSUS (semaglutide tablets) to reduce major adverse cardiovascular events cardiovascular death, nonfatal myocardial infarction or nonfatal stroke in adults with type 2 diabetes who have established cardiovascular disease or are at high risk for these events
Shayestehyekta M, Moradi M
19 Cardiovascular Outcome Trials of SGLTis in Patients with Type 2 Diabetes SGLTis have emerged as potent agents for the reduction in MACE risk, hospitalizations for HF (HFH), and the progression of chronic kidney disease
US$ 24.80
US$ 28.37
US$ 24.62
US$ 29.79
US$ 25.96
US$ 26.26
